Brief: Fennec Pharmaceuticals Announces Positive Topline Results

Fennec Pharmaceuticals

02/12/2025 14:22

Dec 2 (Reuters) - Fennec Pharmaceuticals Inc FENC.O:

FENNEC PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM INVESTIGATOR-INITIATED CLINICAL STUDY OF PEDMARK® IN JAPAN TO REDUCE CISPLATIN-INDUCED HEARING LOSS

FENNEC PHARMACEUTICALS INC - STUDY SHOWS SIGNIFICANT REDUCTION IN HEARING LOSS IN 3-18 YEAR OLDS

FENNEC PHARMACEUTICALS INC - PEDMARK SHOWED NO INTERFERENCE WITH CISPLATIN ANTITUMOR ACTIVITY

FENNEC PHARMACEUTICALS INC - PLANS TO PURSUE REGISTRATION FOR PEDMARK IN JAPAN

Source text: ID:nGNX436j26

Further company coverage: FENC.O

 ((Reuters.Briefs@thomsonreuters.com;))